Whether it’s a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.
BlackBerry Limited (NASDAQ: BBRY) shares retreated on Thursday to close down 8.67 percent after seeing gains of 3.48 percent on Tuesday. The stock traded about 34 million shares and was one of the most active stocks on the NASDAQ. Investors are reacting to Company co-founder and former Chief Executive Officer Mike Lazaridis walking away from a possible takeover plan. Lazaridis has also reduced his stake to under 5% in the company from 8%.
Get more information on BlackBerry Limited and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/BBRY
Textura Corporation (NYSE: TXTR) shares closed down 17.06 percent on Thursday with about 5.6 million shares traded. The stock was one of the biggest decliners in the NYSE. The stock fell as much as 21% earlier in the session, after the staff at Citron Research issued a report calling the company a fraud.
Get more information on Textura Corporation and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/TXTR
TechPrecision Corporation (OTC: TPCS) shares closed up 14.95 percent with about 1.3 million shares traded on Tuesday. The stock was one of the biggest gainers in the OTC market. Earlier in the week, the company, an industry leading global manufacturer of precision, large-scale fabricated and machined metal components and tested systems with customers in the naval/maritime, energy and precision industrial sectors, congratulated Mevion Medical Systems on the milestone event of delivering the world’s first MEVION S250 Proton Therapy System for treatment at the S. Lee Kling Proton Therapy Center at Barnes-Jewish Hospital in St. Louis. A patient with a rare type of cancer called chondrosarcoma at the base of the skull has become the first person in the world to receive proton therapy using the system.
Get more information on TechPrecision Corporation and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/TPCS
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) shares closed down 21.27 percent on Thursday with about 2.3 million shares traded. The stock was one of the biggest decliners on the NASDAQ. The company, a developer of oral drug delivery systems, announced on Tuesday that it has entered into definitive agreements with investors to purchase an aggregate of 1,580,000 shares of common stock at a price of $10.00 per share in a registered direct offering. The offering is expected to close on or about December 31, 2013, subject to the satisfaction of customary closing conditions.
Get more information on Oramed Pharmaceuticals Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/ORMP
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.